Monday, April 24, 2017
Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at page facebook
Viriom Reports Positive Findings in Phase IIb Study of ElpidaŽ as Compared to Efavirenz in Combination with TDF/FTC at CROI 2017
(February 17, 2017)

SAN DIEGO, Feb. 17, 2017 /PRNewswire/ -- Viriom, Inc. announced the top-line results of its Phase IIb comparator study of ElpidaŽ versus Efavirenz (EFV) in combination with Tenofovir/Emtracitabine (TDF/FTC) at the Conference on Retroviruses and Opportunistic Infections (CROI 2017).

The study was presented by Professor Robert Murphy, Northwestern University, Chicago, as a late-breaker poster. In this Phase IIb, randomized, placebo-controlled, double-blind, multicenter study, 120 antiretroviral therapy (ART)-naīve HIV-1-infected patients were treated with once-daily oral dosing with either 20 mg Elpida or 600 mg Efavirenz in combination with TDF/FTC for 48 weeks. Sixty patients were assigned to each of the Elpida and EFV treatment groups.

Both 20 mg Elpida and 600 mg QD EFV treatment groups showed an acceptable decrease in HIV-1 viral loads compared to baseline. More Elpida patients (91.7%) completed treatment than EFV patients (78.3%), and Elpida patients had fewer adverse events (AEs), including central nervous system and skin adverse events.

"We are excited about these clinical results," commented Dr. Vadim Bichko, Viriom's Chief Scientific Officer. "This 48-week study demonstrated equivalent virologic and immunologic efficacy of ART regimens including 20 mg Elpida or 600 mg EFV in ART-naive HIV-1 infected patients. Elpida was significantly better tolerated than EFV-based therapy, offering a safer alternative to EFV-based ART."

About Viriom

Viriom is an emerging leader in the development of innovative antiviral drugs and drug combinations, as well as treatment and diagnosis methods. Viriom's most advanced drug is Elpida/elsulfavirine, a once-daily oral prodrug of VM-1500A, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI). Viriom expects to obtain first market registration for Elpida in 2017. Development is underway for once-weekly oral and longer-acting parenteral formulations of Elpida/elsulfavirine, as well as drug combination formulations. Learn more

Media Contact
Ron Demuth

To view the original version on PR Newswire, visit:

SOURCE Viriom, Inc.

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc., Science, Lifestyle, Medical,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Kidney Dialysis Equipment Market to be Surpass US$ 24.5 Billion by 2024, On the Back of Increasing Prevalence of Chronic Kidney Diseases
  • Minimally Invasive Spine (MIS) Market Current and Future Players Products Pipeline Available in 2017 Report at
  • Global Breast Biopsy Devices Market Expanding At A CAGR Of 10.6% From 2016 To 2022 - Credence Research
  • United States In Vitro Diagnostics Market Estimated to Grow at a CAGR of 4.9% from 2018 to 2023 - Axiom MRC.
  • Global Medical Imaging Software Market Driven by the Increasing Need for Early Diagnosis and Preventive Medicine: Technavio

  • Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
  • Tobacco Companies Gave $1.5 Million to Trump Inaugural and Ramped Up Lobbying - They Want to Roll Back FDA Oversight of E-Cigarettes, Cigars
  • Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
  • Targeting Cancer Cells With an Implantable Drug Delivery System
  • Public Health Campaign Says Dollar General's Illegal Hazardous Waste Treatment is Another Example of Careless Corporate Behavior Endangering Communities

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines